EULAR sets a stricter treatment path for adult antiphospholipid syndrome
Antiphospholipid syndrome (APS) remains one of the clearest examples in rheumatology of a condition where laboratory profile, vascular biology, and pregnancy outcomes intersect. The new EULAR recommendations in adult APS move management toward a risk-stratified model built around antibody profile, prior thrombosis, obstetric history, and the practical realities of long-term anticoagulation. High-risk antiphospholipid antibody patterns carry greater thrombotic and obstetric danger, and the guidance treats that biology as clinically actionable rather than merely descriptive.
A high-risk aPL profile is not a laboratory footnote. It marks a patient population in whom the endothelium, coagulation cascade, and placental circulation are more likely to fail under stress, which is why the recommendations pair disease-specific therapy with cardiovascular risk reduction, venous thrombosis prevention, treatment adherence, and lifestyle counseling. In a syndrome defined by recurrent clotting and pregnancy morbidity, prevention depends on more than choosing an anticoagulant; it depends on suppressing every modifiable trigger that can amplify an already prothrombotic state.
High-risk antibody profiles drive the prevention strategy
The recommendations single out asymptomatic aPL carriers, patients with systemic lupus erythematosus without prior thrombotic or obstetric APS, and non-pregnant women with a history of obstetric APS only, when each has a high-risk aPL profile. For these groups, low-dose aspirin is recommended. The rationale is biologically consistent: platelet activation and vascular inflammation can precede overt thrombosis, and antiplatelet therapy may blunt that early pathway before a first event occurs.
This is a cautious preventive approach, not an indiscriminate one. The guidance reserves aspirin for those in whom antibody burden and clinical context suggest meaningful downstream risk, rather than extending it to every patient with a positive test. In APS, test positivity alone does not equal uniform danger; the combination of antibody pattern and clinical phenotype determines how aggressively prevention should begin.
Venous thrombosis requires long-term vitamin K antagonism
For patients with APS and a first unprovoked venous thrombosis, the recommended treatment is long-term therapy with a vitamin K antagonist and a target international normalised ratio of 2–3. That recommendation reflects the chronic nature of thrombotic risk in APS. Unlike a transient provoking factor, the autoimmune procoagulant tendency persists, and short-course anticoagulation risks leaving patients exposed to recurrent clotting once therapy ends.
The INR target of 2–3 is a deliberate balance between clot prevention and bleeding risk. Warfarin remains the standard here because it allows titration to a measurable biologic effect, which matters in a syndrome where recurrence can be catastrophic and where the evidence base has not supported routine substitution with a direct oral anticoagulant.
Arterial events demand a wider anticoagulation discussion
Patients with APS who have had a first arterial thrombosis are managed differently from those with venous disease. EULAR recommends vitamin K antagonist therapy with either INR 2–3 or INR 3–4, with the choice driven by individual bleeding and thrombosis risk. Arterial thrombosis in APS often reflects a more aggressive vascular phenotype, and higher-intensity anticoagulation may be reasonable when recurrence risk is judged to outweigh hemorrhagic danger.
The recommendation also acknowledges a practical reality: arterial APS is not uniform, and the balance between efficacy and safety cannot be reduced to a single INR target for every patient. Some clinicians will lean toward stronger anticoagulation, others toward standard intensity with close follow-up. The decision depends on where the patient sits on the spectrum of recurrent thrombosis, bleeding vulnerability, and concomitant vascular risk factors.
A single oral anticoagulant does not fit every antiphospholipid profile.
Rivaroxaban is excluded in triple-positive APS
One of the clearest statements in the guidance is the warning against rivaroxaban in patients with APS who are triple aPL positive. Triple positivity signals a particularly high-risk antibody pattern, and the recommendation reflects concern that a direct factor Xa inhibitor may not provide adequate protection in this subgroup. In clinical terms, the issue is not convenience versus inconvenience; it is whether the anticoagulant can suppress the specific thrombotic tendency that APS generates.
For clinicians, this means direct oral anticoagulants should not be assumed interchangeable with vitamin K antagonists in APS. The syndrome is mechanistically distinct from more routine venous thromboembolism, and the guidance draws a firm boundary around one of the most vulnerable serologic phenotypes.
Recurrent thrombosis calls for escalation rather than resignation
When thrombosis recurs despite adequate treatment, the recommendations offer three escalation paths: add low-dose aspirin, raise the INR target to 3–4, or switch to low molecular weight heparin. Each option reflects a different way of responding to persistent clotting pressure. Aspirin may help if platelet-driven arterial biology is contributing; a higher INR may be needed if standard-intensity anticoagulation has failed; low molecular weight heparin can be used when oral therapy is no longer sufficient or practical.
This section of the guidance is clinically important because recurrent APS is often a sign that the patient’s thrombotic threshold has not been lowered enough. Rather than stopping at the first failure, the recommendations encourage active intensification. In a disease where recurrence can involve the brain, heart, lungs, or placenta, waiting for another event is not a neutral choice.
Pregnancy management centers on combined anticoagulation
In women with prior obstetric APS, the recommended regimen during pregnancy is low-dose aspirin combined with prophylactic-dose heparin. The combination targets two related problems: platelet activation and coagulation activation in the placental circulation. Pregnancy itself creates a hypercoagulable state, and APS adds autoimmune endothelial injury and placental dysfunction on top of that baseline risk.
For recurrent pregnancy complications, the recommendations allow further escalation: increasing heparin to therapeutic dose, adding hydroxychloroquine, or adding low-dose prednisolone in the first trimester. These options are reserved for difficult cases, where standard combination therapy has not been enough to prevent loss or placental injury. Hydroxychloroquine may be attractive because of its immunomodulatory effects, while short-course prednisolone is positioned as a selective early-pregnancy adjunct rather than routine therapy.
Evidence remains limited despite the strength of the guidance
The recommendations are firm, but the evidence base behind them is not equally strong across every clinical decision. High-quality data remain limited, which is why expert opinion still plays a major role in several management choices, especially in recurrent thrombosis and recurrent obstetric complications. APS is a syndrome in which randomized trials are difficult, event rates are relatively low in some strata, and the clinical stakes of failure are high.
What these recommendations do provide is a coherent framework: identify high-risk antibody profiles, reduce modifiable vascular risk, use aspirin selectively for prevention, rely on vitamin K antagonists for thrombotic APS, avoid rivaroxaban in triple-positive patients, and intensify treatment when thrombosis or pregnancy morbidity persists. The remaining gap is not conceptual clarity but better evidence for the patients who sit at the margins of these decisions, where the next clot or pregnancy loss is exactly what clinicians are trying to prevent.